Welcome to our dedicated page for Ventyx Biosciences SEC filings (Ticker: VTYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial data, cash runway disclosures, and milestone payments are buried deep in Ventyx Biosciences’ SEC documents. Finding the next hint on its TYK2 inhibitor or NLRP3 program can take hours—and missing an 8-K update could cost you. That’s why investors searching for “Ventyx Biosciences SEC filings explained simply” start here.
Stock Titan extracts the details that matter. Our AI reads every VTYX 10-K and 10-Q the moment they hit EDGAR, then highlights R&D spend, pipeline progress, and liquidity metrics. Want “Ventyx Biosciences quarterly earnings report 10-Q filing” without wading through footnotes? Need “Ventyx Biosciences 8-K material events explained” after a trial readout? We surface it in plain English, alongside real-time alerts for “Ventyx Biosciences Form 4 insider transactions.”
- Track “Ventyx Biosciences insider trading Form 4 transactions” and receive notifications the instant executives buy or sell.
- Compare R&D trends across periods with our “Ventyx Biosciences earnings report filing analysis.”
- Review governance details in the “Ventyx Biosciences proxy statement executive compensation” section, simplified by AI.
Whether you’re monitoring cash burn before the next Phase II readout or checking “Ventyx Biosciences annual report 10-K simplified” for risk factors, our platform keeps you ahead. From “understanding Ventyx Biosciences SEC documents with AI” to spotting “Ventyx Biosciences executive stock transactions Form 4,” every disclosure is translated into actionable insight—updated in real time and ready when you are.
Point72 (Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen) reports beneficial ownership of 5,895,069 shares of Ventyx Biosciences common stock, representing 8.3% of the class as of the close of business on June 30, 2025. The filing clarifies that Point72 Asset Management has shared voting and dispositive power over these Shares held by Point72 Associates, that Point72 Capital Advisors is the general partner, and that Mr. Cohen controls both entities. The statement notes the shares were not acquired to change control of the issuer and that Cubist Systematic Strategies, LLC acts as a sub-advisor for a portion of the reported position.
FAQ
What is the current stock price of Ventyx Biosciences (VTYX)?
What is the market cap of Ventyx Biosciences (VTYX)?
